Tyra Bioscience (TYRA) AI Stock Analysis

• Market Cap: $1.74B
• Dividend Yield: N/A
• Average Volume (3M): 370.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: N/A
• EPS Growth: -17.01%
• Country: US
• Employees: 60
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.57
• Shares Outstanding: 53,372,097
• 10 Day Avg. Volume: 580,167
• 30 Day Avg. Volume: 370,944
• PEG Ratio: -0.39
• Price to Book (P/B): 6.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -16.45
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -12.00K
• Enterprise Value/Ebitda: -13.73
• 1Y Price Target: $48.71
• Price Target Upside: 49.80% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): -2.29
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: $33.00 ▲(1.48% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is held back mainly by weak financial performance (no revenue, widening losses, and rising cash burn despite low leverage). Technicals provide the primary support, with price trading above key moving averages and positive momentum indicators. Valuation contributes little due to the negative P/E and no dividend yield data.

Positive Factors

Focused FGFR-targeted strategy

A concentrated FGFR focus creates a durable strategic niche: by targeting a validated pathway the company can build deep scientific expertise, streamline clinical programs around common biology (FGFR3) and prioritize indications where target validation improves odds of regulatory and clinical success.

Computational, structure-based drug design

Structure-guided and computational design is a sustainable competitive capability: it can increase hit-to-lead efficiency, produce differentiated molecules that address resistance, strengthen IP positions, and raise probability of clinical success across multiple programs over the medium term.

Solid cash runway and low leverage

A reported $256M of cash with runway to at least 2027 and very low debt provides durable financial flexibility to complete key midstage trials and reach clinical inflection points without immediate financing pressure, lowering near-term dilution and execution risk.

Negative Factors

Pre-revenue business model

Being pre-revenue is a structural constraint: the company must fund operations via capital markets or partnerships until approvals and commercialization occur, prolonging dependence on financing and making long-term sustainability contingent on clinical and regulatory success.

Widening losses and rising cash burn

Accelerating losses and negative operating/free cash flow are durable weaknesses: sustained high burn increases likelihood of future financings, could cause dilution, and heightens execution risk if trial timelines or outcomes slip versus plan.

Capital consumption and negative ROE

Declining shareholders' equity and deeply negative ROE show the company is consuming capital to fund R&D; over the medium term this erodes financial cushions and increases reliance on external funding or partnerships to sustain development and advance the pipeline.

Tyra Bioscience Business Overview & Revenue Model

Company Description

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

How the Company Makes Money

Tyra Bioscience makes money primarily through its research and development activities in oncology therapeutics, which are aimed at bringing novel cancer treatments to market. The company generates revenue through strategic partnerships and collaborations with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on product sales if the drugs are successfully commercialized. Additionally, Tyra Bioscience may secure funding through grants and government programs focused on advancing cancer research. As its drugs progress through clinical trials and potentially receive regulatory approval, the company could also earn revenue from direct sales or licensing agreements.

Tyra Bioscience Financial Statement Overview

Summary

Financial profile reflects an R&D-stage biotech: zero revenue across the periods provided, materially widening net losses (to about -$120.0M in 2025) and worsening cash burn (free cash flow about -$95.3M in 2025). The key offset is a low-leverage balance sheet (debt-to-equity ~0.02), but equity declined notably from 2024 to 2025, indicating continued capital consumption.

Income Statement

The company is still pre-revenue (revenue has been $0 across the provided annual periods), so profitability metrics are not yet established. Losses have widened materially over time, with net loss increasing from about -$9.3M (2020) to about -$120.0M (2025), and EBIT also trending more negative (about -$132.8M in 2025 vs. -$104.2M in 2024). The main strength is that results are consistent with an R&D-stage biotech model, but the clear weakness is accelerating operating losses without offsetting revenue traction in the financials provided.

Balance Sheet

Leverage is very low, with total debt of about $5.8M against stockholders’ equity of about $259.2M in 2025 (debt-to-equity ~0.02), which provides financial flexibility. However, equity has declined from about $343.2M (2024) to $259.2M (2025), reflecting ongoing losses and cash usage. Return on equity is meaningfully negative in recent years (about -46% in 2025), highlighting that the capital base is being consumed to fund operations despite the conservative debt profile.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow consistently negative and worsening in 2025 (operating cash flow about -$95.1M; free cash flow about -$95.3M) versus 2024 (about -$69.8M and -$70.4M, respectively). A relative positive is that free cash flow roughly tracks net loss (free cash flow to net income near ~1.0 in recent years), suggesting losses are not heavily driven by non-cash add-backs; however, the underlying issue remains a rising cash burn profile that increases financing dependence until revenue arrives.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-140.00K	0.00	0.00	0.00	0.00	0.00
EBITDA	-122.36M	-132.76M	-103.66M	-79.59M	-58.63M	-26.15M
Net Income	-111.68M	-119.95M	-86.48M	-69.13M	-55.33M	-26.29M
Balance Sheet
Total Assets	301.85M	282.61M	363.56M	225.86M	266.18M	306.70M
Cash, Cash Equivalents and Short-Term Investments	274.92M	256.00M	341.44M	203.47M	251.21M	302.18M
Total Debt	5.92M	5.81M	6.22M	6.50M	2.62M	1.18M
Total Liabilities	21.34M	23.43M	20.41M	21.59M	8.35M	4.96M
Stockholders Equity	280.51M	259.18M	343.15M	204.26M	257.83M	301.74M
Cash Flow
Free Cash Flow	-91.20M	-95.28M	-70.44M	-50.91M	-50.84M	-24.41M
Operating Cash Flow	-91.11M	-95.14M	-69.77M	-50.14M	-50.28M	-23.75M
Investing Cash Flow	45.04M	72.46M	-98.40M	-144.60M	-559.00K	-645.00K
Financing Cash Flow	4.12M	8.10M	202.14M	1.54M	632.00K	311.35M

Tyra Bioscience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 32.52
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TYRA, the sentiment is Positive. The current price of 32.52 is above the 20-day moving average (MA) of 31.23, above the 50-day MA of 29.32, and above the 200-day MA of 17.16, indicating a bullish trend. The MACD of 1.17 indicates Negative momentum. The RSI at 57.21 is Neutral, neither overbought nor oversold. The STOCH value of 64.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TYRA.

Tyra Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KALV	57 Neutral	$811.77M	-4.02	―	―	―	-13.14%
TYRA	56 Neutral	$1.74B	-17.30	-34.75%	―	―	-17.01%
TERN	52 Neutral	$4.47B	-40.73	-29.12%	―	―	12.45%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NRIX	51 Neutral	$1.63B	-5.20	-49.63%	―	48.32%	-1.91%
PVLA	49 Neutral	$1.78B	-10.51	―	―	―	―
GOSS	47 Neutral	$99.20M	-0.62	―	―	-58.17%	-116.24%